Denavir

Quick links to important sections

Denavir

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Denavir

What is Denavir?

Denavir is a topical antiviral medication containing the active ingredient penciclovir. It is specifically formulated as a cream to treat recurrent herpes labialis, commonly known as cold sores or fever blisters, in adults and children.

Mechanism of Action

The active component, penciclovir, targets the herpes simplex virus (HSV). When applied to the affected area, the medication is taken up by virus-infected cells. Once inside these cells, it is converted into an active form that inhibits viral DNA polymerase. By interfering with the virus's ability to replicate its DNA, the medication helps to stop the virus from spreading to healthy cells.

Purpose and Usage

Denavir is intended for the treatment of cold sores that occur on the lips and the skin around the mouth. It is designed to:

  • Decrease the duration of the viral outbreak.
  • Shorten the healing time of the sores.
  • Reduce the period of time during which the site is painful.

While this medication helps manage the symptoms and recovery from an active outbreak, it is not a cure for the herpes simplex virus. The virus remains dormant in the nerve cells between outbreaks, and the medication does not prevent the future transmission of the virus to other individuals.

What side effects are possible with Denavir?

Possible side effects and safety information

The safety profile of Denavir (Penciclovir topical cream) is primarily characterized by localized reactions due to the minimal systemic absorption following external application, as documented in regulatory sources.


Officially Documented Adverse Reactions

Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOC) in regulatory documents. Reactions commonly observed in clinical trials, classified as Common (occurring in ge 1% to < 10% of patients), include headache and various application site reactions.

Reactions categorized under Skin and subcutaneous tissue disorders and General disorders and administration site conditions involve local manifestations such as burning, stinging, localized pain, pruritus (itching), and erythema (redness). The frequency for many of these localized effects is often classified as not known (post-marketing data).


Serious Adverse Reactions and Safety Restrictions

Post-marketing surveillance has documented reports of serious hypersensitivity reactions, including angioedema (swelling of the face, lips, or throat) and anaphylaxis. These represent clinically significant adverse events.

Official labeling defines specific safety limitations. The cream is contraindicated in individuals with known hypersensitivity to the drug or its components. It is strictly for external use on herpes labialis of the lips and face and is not recommended for use on mucous membranes, such as the eyes, inside the mouth, or nose.

Safety and effectiveness have not been established in certain populations, specifically children under 12 years of age or in patients who are immunocompromised.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The overdose profile for Denavir (Penciclovir) cream is fundamentally shaped by its topical route of administration and the resulting poor systemic absorption.

Feature Regulatory Documentation
Documented Manifestations Systemic adverse reactions are unlikely due to the drug's poor oral absorption. No specific overdose information is available in the current prescribing information.
Physiological Effect Local irritation in the mouth could potentially occur following accidental oral ingestion of the cream.

Emergency Action Requirements

Official regulatory guidance is constrained to the potential for accidental ingestion. The U.S. Food and Drug Administration prescribing information states there is no specific information on overdose available for the cream formulation. However, patient resources aligned with official guidance mandate that if the medication has been accidentally swallowed, individuals must seek emergency medical attention.

Treatment for over-application or accidental ingestion is generally described as symptomatic and supportive. Regulatory labeling does not document the existence of a specific antidote for penciclovir. The entire contents of a standard container, if accidentally ingested orally, are not expected to result in untoward systemic effects based on the compound’s poor oral bioavailability. This low likelihood of systemic toxicity means that specific severe or life-threatening outcomes are not documented in the official overdose sections.

Therapeutic Uses of Denavir

What Denavir Treats: Main Uses and Benefits

Denavir cream is a topical prescription medication primarily used for the treatment of recurrent herpes labialis, known commonly as cold sores, in adults and children 12 years of age and older. Its therapeutic focus is on providing symptomatic relief and supporting the management of the overall duration of these localized viral outbreaks on the lips and surrounding face. The primary use is associated with conditions characterized by episodic or fluctuating symptom patterns.

Symptom Management and Clinical Context

This medication is commonly applied across therapeutic domains where additional symptomatic support is needed. It may assist with managing challenging manifestations like tingling, itching, burning, and localized pain associated with the lesions. The medication supports patients during difficult episodes by easing distress and contributing to improved comfort during periods of heightened symptoms.

Supports Healing and Episode Duration

Denavir is relevant for managing symptoms that interfere with daily comfort. It may assist with managing the healing time of the visible lesions and helps with addressing the duration of associated pain. This support assists with maintaining functional stability and generally helps improve day-to-day comfort during symptomatic periods, particularly during the acute phase when symptoms create noticeable physiological strain.


Quick Fact: Relief for Recurrent Symptomatic Episodes Denavir is commonly used when short-term symptomatic assistance is needed for conditions involving recurrent or episodic manifestations confined to the lips and perioral area.

Eligibility and Restrictions for Use

The official regulatory profile for Denavir cream defines specific populations for whom the medicine is either permitted, prohibited, or restricted for use. This information is based strictly on government-approved labeling.

Populations Excluded from Use

The single absolute contraindication is a known hypersensitivity to the active ingredient, penciclovir, its oral prodrug, famciclovir, or any of the components of the cream.

Age and Immune Status Eligibility

Population Regulatory Status
Approved Age Adults and children 12 years of age and older are approved for use.
Pediatric Restriction Safety and effectiveness for children under 12 years of age have not been established.
Immunocompromised The effect of Denavir has not been established in this patient group.
Geriatric Use The adverse event profile in patients 65 years of age and older was found to be comparable to younger patients.

Use During Pregnancy and Lactation

Due to the minimal systemic absorption following topical application, Denavir is not expected to result in fetal exposure during pregnancy. Its use is permitted only if clearly needed. Similarly, the drug is not expected to result in exposure of the child during breastfeeding.

Application Site Restrictions

The medicine is strictly approved for use on herpes labialis on the lips and face. Application to human mucous membranes is not recommended, and application in or near the eyes must be avoided.

What should I know about interactions with other medicines?

The interaction profile for Denavir (penciclovir) cream is fundamentally defined by its topical route of administration and the resulting minimal systemic absorption of the active ingredient. This minimal absorption is the basis for the information found in official regulatory documents.

Interaction scope

Entity Official Regulatory Statement
Medicinal product categories with documented interactions None documented. Regulatory labels do not specify any interacting categories.
Specific interacting medicines (if explicitly listed) None explicitly listed. No single medicinal product is specified as interacting or contraindicated.
Mechanistic basis of interactions (only if stated in label) None documented. No metabolic (e.g., CYP450) or transporter-mediated mechanism is described.
Interactions with Food, Alcohol, or Supplements None documented. Official regulatory sources do not list specific interactions with these substances.

Interaction classifications (high-level)

Classification Official Regulatory Statement
Interaction severity classification Not classified as clinically significant (due to minimal systemic exposure).
Timing-based interaction rules None documented. No mandatory separation windows are required in official labeling.
Interaction-context constraints None, as systemic absorption is negligible.

Resulting interaction structure

The official prescribing information from the U.S. Food and Drug Administration (FDA) explicitly states that no drug interaction studies have been performed with Denavir. Regulatory authorities conclude that systemic drug interactions are unlikely because the systemic concentration of penciclovir following topical application is minimal. Consequently, official documentation does not list any contraindicated combinations, timing-based restrictions, or specific interactions with other medicinal products.

Mechanism of Action

Targeting the Virus with Selective Activation

The mechanism of action begins with Penciclovir's selective targeting of the Herpes Simplex Virus (HSV) enzyme, Viral Thymidine Kinase (TK). This enzyme, found almost exclusively in infected cells, performs the necessary step of activating the drug by converting it into its active form, Penciclovir Triphosphate. This highly specific phosphorylation cascade ensures the active metabolite is predominantly accumulated within virus-infected cells, a mechanism defined by enzyme-mediated signaling.

Replication Halt via DNA Polymerase Inhibition

The active triphosphate molecule functions as a counterfeit building block, acting as a competitive inhibitor of the Viral DNA Polymerase. This interaction fundamentally blocks the process of viral DNA synthesis. Arresting the genetic replication sequence initiates a molecular cascade that restricts the production and movement of new viral particles, thereby modulating the viral life cycle. The sustained inhibition of viral replication reduces the local viral burden at the target cells. The consequence of reducing the local viral burden facilitates the intrinsic epithelial repair processes.

Dosage and Administration Information

Official Administration Instructions for Denavir (penciclovir) Cream

Denavir is a topical 1% cream, and its official use is governed by a strict, time-sensitive protocol. It is approved for use in adults and pediatric patients 12 years of age and older.


Dosing Schedule and Duration

Administration Detail Official Instruction
Route of Administration Topical use only, applied to the affected area on the lips and face.
Dosing Frequency Apply every 2 hours during waking hours.
Course Duration The treatment period must not exceed 4 days.

Procedural Steps and Timing

Treatment must be initiated as early as possible, ideally during the prodrome (the initial stage of symptoms like tingling or itching) or immediately upon lesion appearance.

  1. Preparation: Hands should be washed with soap and water before and after application. The treatment area should be clean and dry.
  2. Application: A layer of the 1% cream, sufficient to cover all visible cold sore lesions and the immediately surrounding symptomatic skin, must be applied and gently rubbed in until it disappears.
  3. Constraints: The cream should only be used on the lips and face. Application to human mucous membranes (e.g., inside the mouth or nose) or near the eyes is not recommended.

Recent Clinical Evidence

Research Evidence Overview for Denavir (Penciclovir Cream)


Evidence for Use in Recurrent Herpes Labialis (Cold Sores)

The clinical evaluation of Denavir cream was studied in research examining individuals with recurrent herpes labialis, commonly known as cold sores, on the lips and surrounding areas. Research examining this medicine relies on large-scale, randomized controlled trials (RCTs). These studies were structured to compare the use of penciclovir cream against a vehicle-only cream (placebo) to monitor clinical measurements during the course of the outbreak. The evidence derived from these trials contributes to the broader evidence landscape related to the short-term symptom patterns of this condition.

What Researchers Studied and Key Outcomes Measured

Researchers applied the cream in studies conducted during periods of increased symptom activity, specifically when a cold sore outbreak began. The trials included immunocompetent adults and children 12 years of age and older who had a history of these recurring episodes. Studies also examined how measured outcomes varied based on the timing of treatment initiation, whether at the earliest sign of symptoms (such as tingling or burning) or later, once a visible lesion had already developed.

The study outcomes examined in these clinical trials focused mainly on short-term, acute changes. These primary outcomes related to physical discomfort and the overall duration of the episode. Specifically, researchers monitored the time to complete resolution of classical lesions and the duration of lesion-associated pain.


Findings Reported in Clinical Trials

The findings reported across the major clinical trials and summarized in regulatory documents described patterns related to the time taken for the cold sore episode to resolve, where the group using the cream was associated with numerically shorter durations compared to the control group. Studies monitored the duration of pain and reported measurements showing that this symptom was associated with patterns of resolving earlier in the group receiving penciclovir cream. However, the reported numerical differences observed in these short-term outcomes were consistently characterized in the scientific literature as being small in magnitude across the evidence base.

What is Still Uncertain About Denavir (Evidence Gaps)

The studies monitored acute, episodic changes, but long-term effects on recurrence frequency or functional outcomes are not well characterized. Additionally, there is limited information regarding the application of the cream to human mucous membranes, such as the inside of the mouth, which restricts where the product is studied for use. Certainty regarding extrapolation remains low for populations outside of immunocompetent adults and children 12 and older.

Frequently Asked Questions (FAQ)

Common questions about Denavir (FAQ)


Q: Is Denavir the same thing as Valtrex or Acyclovir?

Denavir's active ingredient is penciclovir, which belongs to the same pharmacological class of drugs—antiviral nucleoside analogs—as Acyclovir and Valtrex (valacyclovir). However, they are distinct chemical compounds, although they belong to the same pharmacological class of antiviral agents and nucleoside analogs.


Q: What's the difference between Denavir cream and oral antiviral pills for cold sores?

Denavir is a topical cream applied directly to the site of the cold sore on the lips and face. Because it is used externally, official studies show it is associated with minimal systemic absorption. Oral antiviral pills, in contrast, are taken by mouth and are absorbed systemically throughout the body.


Q: What happens if you accidentally swallow a small amount of Denavir?

Accidental ingestion of a small amount is not typically associated with serious risks in adults, given the minimal systemic absorption of the active ingredient. As with any medication ingestion, consulting a poison control center is an appropriate safety measure.


Q: Does Denavir interact with common lip balms or moisturizers?

Official regulatory documents do not specify any drug interaction studies performed with topical non-medicinal products like lip balms or moisturizers. Since systemic drug interactions are unlikely due to minimal systemic absorption, no interactions with other topical products are documented in the official regulatory labeling.


Q: Does Denavir have any documented interactions with over-the-counter pain relievers?

The official documentation states that no formal drug interaction studies have been performed with Denavir cream. Therefore, the product label does not list specific interactions with over-the-counter pain relievers, and systemic drug interactions are considered unlikely due to minimal absorption.


Q: Are there any warnings about driving or operating machinery while using Denavir?

The official labeling does not include a specific warning regarding the ability to drive or operate heavy machinery. The lack of specific warnings is consistent with the minimal systemic absorption of the product, which is not expected to affect central nervous system function.


Q: What is the typical age range for people who are prescribed Denavir?

Denavir cream is officially approved for use in adults and children 12 years of age and older for the treatment of recurrent herpes labialis. Safety and effectiveness in children under 12 years of age have not been established according to official regulatory information.


Q: Does applying Denavir too late make it less effective?

Official instructions and study data emphasize starting treatment as early as possible—ideally at the first sign of symptoms, such as tingling or itching (the prodrome). Treatment initiated later has been associated with less clear benefit in clinical trials.


Q: Can Denavir be used for sores other than those caused by HSV-1?

Denavir is indicated only for treating recurrent herpes labialis (cold sores) on the lips and face. The cream is not approved for use on other types of sores, according to official regulatory documents.


Q: Is Denavir less effective if the expiry date has recently passed?

Official guidelines specify that all medicines must be stored properly and discarded if they are unused or have expired. Medications should not be used past the printed expiration date, as their full effectiveness and quality cannot be assured.


Q: Can Denavir interact with prescription medications for chronic conditions?

No formal drug interaction studies have been conducted. Systemic interactions with chronic medications are unlikely due to the minimal systemic absorption of the active ingredient after topical application.


Q: Does Denavir contain any ingredients that can dry out the skin?

The cream formulation contains inactive ingredients such as propylene glycol, cetostearyl alcohol, and white petrolatum. The official labeling does not include a specific warning about the formulation causing skin dryness.


Q: Is there a generic version of Denavir available?

Yes, the FDA has approved generic versions of penciclovir cream, the active ingredient in Denavir. Generic availability is subject to local markets and regulatory conditions.


Q: Are there any specific foods or drinks to avoid while using Denavir?

Official regulatory documents do not list any specific interactions with food or drinks. Because the cream is absorbed minimally into the bloodstream, no mandatory dietary restrictions are required during treatment.


Q: Do doctors ever prescribe Denavir for non-lip related herpes outbreaks?

Denavir is officially approved only for the treatment of herpes labialis on the lips and face. The label states that application to human mucous membranes, such as the inside of the mouth or nose, is not recommended.


Q: Is Denavir absorbed into the bloodstream significantly after topical application?

Official pharmacokinetic studies indicate that there is minimal systemic absorption of penciclovir following topical application of Denavir cream.


Q: Why is the application amount for Denavir described as a thin film?

The official instructions specify applying a layer of the cream sufficient to cover all visible lesions and the immediately surrounding symptomatic skin. This instruction aims to ensure adequate coverage over the affected area.


Q: Can people with a known allergy to other antivirals still use Denavir?

Denavir is contraindicated, meaning it should not be used, by anyone with a known hypersensitivity or allergy to its active ingredient, penciclovir, its oral prodrug, famciclovir, or any other component of the cream.


Q: What are the rules regarding alcohol consumption while using Denavir?

The official documentation does not list any specific interactions or warnings concerning alcohol consumption while using Denavir cream. Due to the minimal systemic absorption, alcohol consumption is generally not a concern during topical treatment.

How should Denavir be stored and disposed of?

How to Store and Dispose of Denavir (Penciclovir Cream)

Official regulatory guidelines strictly define the conditions required for storing and discarding Denavir cream.

Storage Requirements

Denavir must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in the container it came in, tightly closed, and stored away from excess heat and moisture. Storage must ensure the medication is out of the sight and reach of children.

Disposal Instructions

Unused or expired Denavir cream must not be disposed of by flushing it into the sanitary sewer system or throwing it in the household trash. Disposal must occur in accordance with local requirements for pharmaceutical waste to prevent release into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Denavir found in:

A-Z Index: